Azeria Therapeutics announces £32.0 million series B financing

  • Syncona leads £32.0 million Series B financing of Azeria Therapeutics with a £29.5 million commitment
  • Opportunity to address a significant unmet need in oestrogen receptor positive breast cancer patients in lead programme and to build a world class pioneer factor oncology company 

London, 21 November 2019 – Azeria Therapeutics (Azeria), a newly formed pioneer factor drug discovery company, today announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund. 

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH